Can immunoglobulin therapy cut infection risk in rituximab patients?

This study followed 73 people with autoimmune diseases like rheumatoid arthritis or multiple sclerosis who were starting treatment with rituximab, a drug that suppresses the immune system. The goal was to track how many developed serious infections and identify who was most at risk. Researchers also looked at whether giving intravenous immunoglobulins could help prevent these infections. The findings aim to guide safer use of rituximab and improve patient monitoring.